{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:34:17Z","timestamp":1791470057912,"version":"4.3.4"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Three single\u2010dose and one multiple\u2010dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin\/kexin type 9 (<jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9) inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were (1) ascending, single, intravenous (<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>) bococizumab (0.3, 1, 3, 6, 12, or 18\u00a0mg\/kg), or placebo (N<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>48; baseline low\u2010density lipoprotein cholesterol [<jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C] \u2265130\u00a0mg\/dL); (2) single, <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> bococizumab (0.5 or 4\u00a0mg\/kg; no placebo) added to ongoing atorvastatin 40\u00a0mg\/day (N<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>24); (3) single, fixed, subcutaneous (<jats:styled-content style=\"fixed-case\">SC<\/jats:styled-content>) bococizumab (100 or 200\u00a0mg), or <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> bococizumab (200\u00a0mg; no placebo; N<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>49; baseline <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C\u00a0\u2265130\u00a0mg\/dL); and (4) weekly <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> bococizumab (0.25, 0.5, 1, or 1.5\u00a0mg\/kg) or placebo for 4\u00a0weeks (N<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>67; baseline <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C\u00a0\u2265130\u00a0mg\/dL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Bococizumab pharmacokinetics were well characterized following single <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">SC<\/jats:styled-content> doses and following multiple <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> doses. Exposure to single\u2010dose bococizumab increased slightly greater than dose\u2010proportionally and clearance decreased with increasing dose. In the single\u2010dose studies, maximal mean percent reductions from baseline in <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C ranged from 43% (0.3\u00a0mg\/kg) to 84% (18\u00a0mg\/kg) in bococizumab\u2010treated subjects, compared with 2% for placebo. For the multiple\u2010dose study, maximal reductions in <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C ranged from 55% (0.25\u00a0mg\/kg) to 66% (1\u00a0mg\/kg) in bococizumab\u2010treated subjects, compared with 9% for placebo. In all studies, adverse events were infrequent, transient, and not dose\u2010related.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bococizumab was generally safe and well tolerated. Bococizumab lowered <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C levels substantially in all four studies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12309","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T20:16:39Z","timestamp":1509135399000},"source":"Crossref","is-referenced-by-count":14,"title":["The effects of single\u2010 and multiple\u2010dose administration of bococizumab (<scp>RN<\/scp>316\/<scp>PF<\/scp>\u201004950615), a humanized IgG2\u0394a monoclonal antibody binding proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-289X","authenticated-orcid":false,"given":"Barry","family":"Gumbiner","sequence":"first","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenshang","family":"Joh","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liang","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wan","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Levisetti","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Vana","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Shelton","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Forgues","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Billotte","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Pons","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Baum","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics Inc.  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela D.","family":"Garzone","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco and San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0335507100"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13451"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvw194"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.11.010"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0009-9163.2004.0238.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fca.15.78"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/VHRM.S102564","article-title":"PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab","volume":"12","author":"Blom DJ","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.187419"},{"key":"e_1_2_9_11_1","article-title":"Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic subjects on high\u2010dose statin","volume":"12308","author":"Fazio S","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.02.006"},{"key":"e_1_2_9_13_1","unstructured":"Pfizer.Pfizer discontinues global development of bococizumab its investigational PCSK9 inhibitor.2016;http:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accessed July 11 2017."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1279602"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.05.010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614062"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701488"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1330849"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105803"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.986"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.007"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201832"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60771-5"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"e_1_2_9_27_1","unstructured":"Amgen.Repatha (evolocumab)\u2014Full prescribing information.2015;https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125522s000lbl.pdf. Accessed July 5 2017."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/fca.13.107"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.07.015"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700437-JLR200"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.867"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.319764"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0141"},{"key":"e_1_2_9_34_1","unstructured":"World Health Organization.WHO statement on public disclosure of clinical trial results.2015;http:\/\/www.who.int\/ictrp\/results\/reporting\/en\/. Accessed July 3 2017."},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMe1705439","article-title":"Data sharing statements for clinical trials \u2014 a requirement of the International Committee of Medical Journal Editors","volume":"376","author":"Taichman DB","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22713"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:06:09Z","timestamp":1695967569000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/1755-5922.12309"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12309","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,23]]},"article-number":"e12309"}}